On August 07, 2023, Poseida Therapeutics, Inc. closed the transaction. The transaction included participation from a single investor.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.735 USD | +0.92% | -6.27% | -19.94% |
05-02 | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
05-01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.94% | 263M | |
+2.75% | 108B | |
+10.25% | 104B | |
+2.42% | 22.33B | |
-11.82% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.15% | 17.64B | |
+6.41% | 14.05B | |
+35.50% | 12.51B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Poseida Therapeutics, Inc. announced that it has received $24.999999 million in funding from Astellas US, LLC